MedTrace Logo

Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma

NCT03057626 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 376

Last updated 2026-01-09

No results posted yet for this study

Summary

This research trial studies late effects after treatment in patients with previously diagnosed high-risk neuroblastoma. Studying late effects after treatment may help to decide which treatments for high-risk neuroblastoma are better tolerated with less side effects over time.

Conditions

  • Recurrent Neuroblastoma
  • Stage 2A Neuroblastoma
  • Stage 2B Neuroblastoma
  • Stage 3 Neuroblastoma
  • Stage 4 Neuroblastoma
  • Stage 4S Neuroblastoma

Interventions

OTHER

Cytology Specimen Collection Procedure

Undergo collection of blood and urine

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Quality-of-Life Assessment

Ancillary studies

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Children's Oncology Group

    lead NETWORK

Principal Investigators

  • Tara O Henderson · Children's Oncology Group

Eligibility

Min Age
5 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-05
Primary Completion
2021-09-30
Completion
2026-09-30

Countries

  • United States
  • Australia
  • Canada
  • New Zealand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03057626 on ClinicalTrials.gov